Sexually Transmitted Disease, Vaginitis and Urinary Tract Infections: Great Results in African Trials

Trials in Ghana, West Africa, on Malaria victims using a new recently patented advanced colloidal silver solution have had some pleasant side effects. Not only did the advanced silver solution have amazing effects on the malaria, but it also proved to be effective against Urinary Tract Infections, Sexually Transmitted Diseases such as gonorrhea, skin infections and parasites that were also present in those malaria patients. West Africa is riddled with all kinds of nasty diseases, so there was no harsher environment for this trial.

The new advanced silver solution is produced by American Biotech Labs and marketed by Nutronix International. American Biotech Labs supplied about 1000 of the 8oz bottles of the advanced colloidal silver for the Ghanaian human trials. The trials were conducted across 4 Ghanaian clinics/hospitals. The silver solution is known to be effective against a broad spectrum of pathogenic bacteria, viruses, molds and yeasts, yet it does not harm the friendly bacteria that we need in our stomach for digestion.

The Ghanaian human trials support many US laboratory trials conducted by a number of top US university and research establishments. Although, colloidal silver has been around for decades having originally been patented in 1924, this new advanced colloidal silver solution has been able to demonstrate a new technology and capabilities. This culminated in a new patent in 2006, representing a major advance in this area.

Numerous claims are made by the patent application that was accepted in 2006. Amongst the patents claims is that it exhibits antimicrobial properties against microbes including gonorrhea, urinary tract infections, vaginal infections, trichomonas vaginalis and Candida albicans. These claims have been independently accepted and validated by the US Patent Office due to the level of hard evidence supporting the claims. This evidence includes the Ghanaian malaria trials.

In US laboratory trials it was established that due to the high potency of the new advanced colloidal silver and its multiple kill mechanisms against bacteria and viruses; urinary tract infections and sexually transmitted diseases could be killed at extremely low concentrations of the silver suspension in water.

Urinary tract infections such as Pseudomonas Aeruginosa was killed at just 5.0 parts per million (that is 5 parts of silver to 999,995 parts of water) whilst other urinary tract infections; Streptococcus Faecalis, E.Coli, Klebsiella Pneumoniae, Enterobacter Aerpyogenes were killed at a mere 2.5 parts per million.

Furthermore, the yeast infection, Candida albicans and the vaginitis infection Trichomonas vaginalis were both killed at only 10.0 parts per million.

There are actually many more bacteria, viruses, molds and yeasts listed on the patent, which are not relevant to this article.

The advanced silver solution is commercially available at 14 parts per million, which is clearly strong enough for most requirements, whilst still being at extremely low concentrations. Most other colloidal silvers have to be hundreds or even thousands of parts per million to even come close to achieving the same results.

The potency at such low concentrations results from the unique manufacturing method. It makes the new silver solution even safer as the vast majority of its mass is just pure water. The new advanced silver solution is a clear transparent liquid, whilst most other colloidal silvers usually have a brown tinge to them and there is hardly any taste to it.

Evidence from the Ghanaian human trials, has been used by American Biotech as part of their application for the first colloidal silver patent in over eight decades being awarded.